Centessa Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Centessa Pharmaceuticals est Saurabh Saha, nommé en Jan2021, a un mandat de 3.83 ans. La rémunération annuelle totale est $ 2.71M, composée du salaire de 24.1% et des bonus 75.9%, y compris les actions et options de la société. détient directement 0.4% des actions de la société, d'une valeur de € 8.60M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.3 ans et 3.8 ans.

Informations clés

Saurabh Saha

Directeur général

US$2.7m

Rémunération totale

Pourcentage du salaire du PDG	24.1%
Durée du mandat du directeur général	3.8yrs
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	1.3yrs
Durée moyenne du mandat des membres du conseil d'administration	3.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Saurabh Saha a-t-elle évolué par rapport aux bénéfices de Centessa Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$161m
Jun 30 2024	n/a	n/a	-US$157m
Mar 31 2024	n/a	n/a	-US$138m
Dec 31 2023	US$3m	US$652k	-US$151m
Sep 30 2023	n/a	n/a	-US$157m
Jun 30 2023	n/a	n/a	-US$173m
Mar 31 2023	n/a	n/a	-US$212m
Dec 31 2022	US$10m	US$621k	-US$216m
Sep 30 2022	n/a	n/a	-US$234m
Jun 30 2022	n/a	n/a	-US$220m
Mar 31 2022	n/a	n/a	-US$197m
Dec 31 2021	US$16m	US$573k	-US$381m

Rémunération vs marché: La rémunération totale de Saurabh ($USD 2.71M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.65M ).

Rémunération et revenus: La rémunération de Saurabh a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Saurabh Saha (48 yo)

3.8yrs

Titularisation

US$2,705,874

Compensation

Dr. Saurabh Saha, M. D., Ph. D. serves as an Independent Director at Clarivate Plc since May 04, 2023. He serves as the Chief Executive Officer at Centessa Pharmaceuticals plc (formerly Centessa Pharmaceut...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Saurabh Saha	CEO & Director	3.8yrs	US$2.71m	0.40% € 8.6m
David Chao	Chief Administrative Officer	3.6yrs	US$1.32m	0.10% € 2.2m
John Crowley	CFO and Principal Financial & Accounting Officer	less than a year	pas de données	pas de données
Tia Bush	Chief Technology & Quality Officer	1.3yrs	pas de données	0.059% € 1.3m
Kristen Sheppard	Senior Vice President of Investor Relations & Corporate Communications	2.4yrs	pas de données	pas de données
Iqbal Hussain	General Counsel	3.8yrs	pas de données	0.071% € 1.5m
Karen Anderson	Chief People Officer	2yrs	pas de données	0.054% € 1.2m
Gregory Weinhoff	Chief Business Officer	less than a year	US$3.31m	0.054% € 1.2m
Mario Accardi	President of the Orexin Program	less than a year	pas de données	pas de données
Ellie Im	Senior Vice President of Clinical Development & Oncology	1.1yrs	pas de données	pas de données
Charlene Stoudt	Senior Vice President of Clinical Development Operations	less than a year	pas de données	pas de données

1.3yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 260 n'est pas considérée comme expérimentée (ancienneté moyenne 1.3 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Saurabh Saha	CEO & Director	3.8yrs	US$2.71m	0.40% € 8.6m
Francesco de Rubertis	Independent Non-Executive Chairman of the Board	4yrs	pas de données	pas de données
Mary Hedley	Independent Non-Executive Director	3.8yrs	US$252.69k	0% € 0
Brett I. Zbar	Independent Non-Executive Director	3.8yrs	US$257.69k	0% € 0
Arjun Goyal	Independent Non-Executive Director	3.8yrs	US$260.19k	0% € 0
Samarth Kulkarni	Independent Non-Executive Director	3.8yrs	US$255.19k	0% € 0
Carol Stuckley	Independent Non-Executive Director	3.5yrs	US$262.69k	0% € 0
Mathias Hukkelhoven	Independent Non-Executive Director	2.3yrs	US$247.69k	0% € 0

3.8yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 260 sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).

Centessa Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

CEO & Director recently sold €801k worth of stock

Chief Business Officer recently sold €234k worth of stock

Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes

Insufficient new directors

Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer

High number of new and inexperienced directors

Recent updates

Centessa Pharmaceuticals Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist

CEO & Director recently sold €801k worth of stock

Chief Business Officer recently sold €234k worth of stock

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million.

Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes

Insufficient new directors

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc Announces Open IND for ORX750

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia

Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc

New major risk - Revenue and earnings growth

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors

New major risk - Share price stability

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Centessa Pharmaceuticals plc Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia

Centessa Pharmaceuticals Announces Karen Anderson as New Chief People Officer

High number of new and inexperienced directors

The Law Offices of Vincent Wong Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc Announces Departure of Javad Shahidi as Chief Medical Officer

Centessa Pharmaceuticals plc Announces Class Action Lawsuit Against Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, Phd, as Senior Vice President of Regulatory Affairs

Centessa Pharmaceuticals plc Announces Executive Changes

Centessa Pharmaceuticals plc Announces Board Changes

Centessa Pharmaceuticals plc Announces Poster Presentation of First Preclinical Data for LockBody Program At 2022 ASCO Annual Meeting

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Centessa Pharmaceuticals plc, Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Centessa Pharmaceuticals Doses First Subject in Global Phase 3 Action Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

Centessa Pharmaceuticals Limited Announces Resignation of Robert M. Califf as Member of the Board of Directors

Centessa Pharmaceuticals plc Together with Subsidiary Palladio Biosciences, Inc. Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease and Reports Initial Positive Safety Data from ALERT Study

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen